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Available online 3 March 2017Emerging and re-emerging pathogens represent a substantial threat to public health, as demonstrated with nu-
merous outbreaks over the past years, including the 2013–2016 outbreak of Ebola virus in western Africa.
Coronaviruses are also a threat for humans, as evidenced in 2002/2003 with infection by the severe acute respi-
ratory syndrome coronavirus (SARS-CoV), which causedmore than 8000 human infectionswith 10% fatality rate
in 37 countries. Ten years later, a novel human coronavirus (Middle East respiratory syndrome coronavirus,
MERS-CoV), associated with severe pneumonia, arose in the Kingdom of Saudi Arabia. Until December 2016,
MERS has accounted for more than 1800 cases and 35% fatality rate. Finding an animal model of disease is key
to develop vaccines or antivirals against such emerging pathogens and to understand its pathogenesis. Knowl-
edge of the potential role of domestic livestock and other animal species in the transmission of pathogens is of
importance to understand the epidemiology of the disease. Little is known about MERS-CoV animal host range.
In this paper, experimental data on potential hosts for MERS-CoV is reviewed. Advantages and limitations of dif-
ferent animal models are evaluated in relation to viral pathogenesis and transmission studies. Finally, the rele-
vance of potential new target species is discussed.ptidase
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Over the past years, outbreaks of zoonotic diseases and growing resis-
tance against antibiotics have emphasized the need for interdisciplinary
collaboration between human health, veterinary medicine and environ-
mental sciences, a concept commonly known as “One health” [1]. Most of
emerging diseases are zoonotic [2]. For instance, the human ﬂu pandemics
have originated in domestic animals and wildlife, and have been driven by
ecological, behavioral, or socioeconomic changes [3]. In these cases, the re-
action time between detection of a new outbreak and application of medi-
cal countermeasures are critical in terms of epidemic control. To
understand the potential role that animal sources could play in virus dis-
semination and the epidemiology of the disease, surveillance studies, as
well as experimental infections inpotential target species, are required. Fur-
thermore, after having identiﬁed the novel or re-emerged virus responsible
of the outbreak, it is important to rapidly provide an accurate diagnosis as a
basis forquarantinemeasures. It is also imperative to focuson the search for
new vaccines and treatments for highly pathogenic viruses, especially for
those that represent a threat to human and animal health, particularly
livestock.
Until the beginning of the last decade, human coronaviruses (HCoV)
infectionswere considered to be restricted to theupper respiratory tract
(URT), with low mortality rate, and recognized as the second ranked
cause of the common cold after rhinoviruses [4]. However, in the late-
2002, the severe acute respiratory syndrome coronavirus (SARS-CoV)
emerged in China. It rapidly spread worldwide with more than 8000
causalities and a lethality rate of 10% [5]. Ten years later, a novel HCoV
associated with severe pneumonia emerged in the Kingdom of Saudi
Arabia [6]. The new CoV was named Middle East respiratory syndrome
coronavirus (MERS-CoV), and by March 2014, a total of 207 cases and
45% fatalities were recorded. Onemonth later, only in April 2014, an in-
crease in human cases was registered with at least 217 more infected
people and 38 fatalities. More recently, as of December 2016, 1842
cases of MERS-CoV have been reported to the World Health Organiza-
tion (WHO), including at least 652 deaths [7].
Besides coronaviruses, highly pathogenic viruses belonging to other
families represent a threat to either human or animal health, or both.
One of the most recent examples is the outbreak of Ebola virus
(Filoviridae) inWest Africa, which started in December of 2013 in Guin-
ea and evolved as the largest Ebola outbreak recorded with more than
28,600 cases [8]. Furthermore, during recent years, outbreaks caused
by other emerging viral pathogens from Arenaviridae, Bunyaviridae,
and Flaviviridae families among others, disturbed public and private
health, social networks and the economies of the affected countries [9,
10]. Prevention and control of emerging and reemerging viral diseases
is efﬁcient when several actions are combined: i.e. creating diagnostic
networks and surveillance programs, training medical and veterinary
staff, informing the population about sanitary measures, and also pro-
moting research on prophylaxis, treatments and on the causative
agent pathogenesis. Regarding the last point, animal models are crucial
to study the viral and host factors contributing to the disease as well as
transmission outcomes of virus infection and to allow pre-clinical test-
ing of antiviral drugs and vaccines. Non-human primates (NHP) are
the preferred models for pathogenesis studies, and potential vaccine
and treatment testing, as they better translate to humans [11]. However,
working with NHP is costly, with limited availability, and raises ethical
problems. Therefore small-animal models are usually the ﬁrst choice
for drug screening. The United States Food and Drug Administration's
(FDA) Animal Rule provides guidelines concerning the appropriateness
of animal models for licensing purposes [12]. Additionally, by control-
ling the disease in animal reservoirs and/or in intermediate hosts,
virus transmission to humans can be signiﬁcantly reduced [13,14].
This is particularly true for domestic or feral animals for which efﬁcient
vaccines and vaccination strategies can be implemented [15]. Therefore,
in cases of new pathogenic virus outbreaks, the search for natural hosts
or potential target animals (as opposed to laboratory animals) seems tobe relevant not only to implement prophylactic solutions but also to im-
prove the preparedness for an eventual global extension of diseases.
Nowadays, this task is rendered possible by the availability of improved
biosafety levels 3 and 4 (BSL3 and 4) animal facilities, which can accom-
modate large animal experimentation with such highly virulent patho-
gens [16].
In this article, the current situation of comprehension on potential
hosts for MERS-CoV is reviewed. Based on the coronaviruses experi-
ence, beneﬁts and limitations of these species as animal models and
transmission studies are discussed.
2. Animal models for MERS research
Several review articles have described and discussed animal models
for MERS-CoV infection [17–20]. In this section, the current status of an-
imal models for MERS disease reproduction is brieﬂy summarized.
After the identiﬁcation of MERS-CoV in 2012 [6], the efforts were di-
rected to develop an animalmodel to study pathogenesis and to test the
efﬁcacy of vaccines and/or treatments in vivo. Similar to SARS-CoV,
rhesus macaques have demonstrated susceptibility to MERS-CoV [21–
23]. A work led by Munster demonstrated that the common marmoset
is also suitable as a MERS-CoV model [24]. They showed that this
model recapitulates the disease observed in humans; therefore,ﬁndings
in the evaluation of potential therapeutic strategies might be imple-
mented in humans. However, small animals are required for controlled,
large and comprehensive studies.While, atﬁrst, experienceswith SARS-
CoV turned out to be very helpful for the research onMERS-CoV, the de-
velopment of a small animal model for MERS was a more difﬁcult task
[18,19]. Raj and collaborators rapidly identiﬁed dipeptidyl peptidase-4
(DPP4) as the functional receptor for MERS-CoV [25], and DPP4 is pres-
ent in lung cells ofmany rodents. Thus, rodentswere expected to be sus-
ceptible for MERS-CoV. However, and as predicted by the crystal
structure analysis of the MERS-CoV receptor binding domain (RBD)
with the human DPP4 (hDDP4) extracellular domain [26], so far, no ro-
dent model is naturally permissive for MERS-CoV infection. In Syrian
hamster, the DPP4 receptor was shown to be expressed on bronchiolar
epithelium, but inoculation of MERS-CoV via aerosols or intratracheal
routes with different doses did not lead to productive infection [27].
Wild type and immune-deﬁcient mice were also tested for MERS-CoV
infection without success [28]. Since then, several groups have been fo-
cused on new strategies to develop a small animal model susceptible to
MERS-CoV infection. It was found that mouse cells could be made per-
missive for MERS-CoV when expressing hDPP4. Consequently, the
hDPP4 was transduced into mouse lungs using an adenovirus vector,
which resulted in animals susceptible to MERS-CoV infection. These
mice exhibited pneumonia and extensive inﬂammatory-cell inﬁltration
with the presence of virus in the lungs [29]. Recently, a transgenic mice
model expressing hDPP4, highly susceptible to MERS-CoV infection and
able to display systemic lesions, has been developed [30]. As demonstrated
for several diseases, transgenic animal models have become an important
tool to improve medical research [31]. On the other hand, glycosylation of
the murine DPP4 is a major factor impacting the receptor function by
blocking the binding to MERS-CoV [32]. Therefore, the modiﬁcation of the
mouse genome tomatch the sequence in the hDPP4made this species sus-
ceptible to MERS-CoV infection [33]. Accordingly, these newly established
micemodels are useful to evaluate the efﬁcacy of vaccines and therapeutic
agents against MERS-CoV infection [30,34–36]. VelocImmune and
VelociGene technologies have been used to develop a humanized mouse
model for MERS-CoV infection [36]; these methodologies can be also ap-
plied for other pathogens in future emerging epidemics.
3. MERS-CoV animal reservoir and the role of domestic animals
Researchersworldwidehave identiﬁed several animal specieswhich
could have a role in the transmission of MERS-CoV to humans (summa-
rized in Fig. 1). Bats have been suggested to be the reservoir for MERS-
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several bat families (Vespertillionidae, Molosidae, Nycteridae and
Emballonuridae) in Africa, America, Asia and Europe [37,38]. Recently,
an experimental infection with Jamaican fruit bats (Artibeus
jamaicensis) conﬁrmed that MERS-CoV can replicate in bats [39]. How-
ever, MERS-CoV strains causing disease in humans have not been so
far identiﬁed in bats. The presence of MERS-CoV neutralizing antibodies
has been reported in dromedary camels (Camelus dromedaries) [40,41]
and, more recently, a link between MERS-CoV infection in camels and
a human infection in Qatar has been suggested [42–45]. Most impor-
tantly, the MERS-CoV strain that caused the 2015 human outbreak
was found in dromedary camels; in fact, phylogenetic analyses indicate
that MERS-CoV was generated in this species by recombination [46]. In
addition, Adney and collaborators have provided experimental evi-
dence to support the role of dromedary camels as aMERS-CoV reservoir
[47]. Recently, evidence was provided that other members of the
Camelidae family such as alpaca (Vicugna pacos) and llama (Lama
glama), are also susceptible to MERS-CoV infection [48–50]. Field stud-
ies with alpacas performed in Qatar conﬁrmed this ﬁnding [51]. A re-
cently published experimental study has demonstrated that domestic
pigs are also susceptible toMERS-CoV infection, suggesting the possibil-
ity of MERS-CoV circulation in other unsuspected animal species such
suidae [50]. While DPP4 in silico predictions and in vitro studies suggested
that other livestock species such as goats, sheep, or horses could be suscep-
tible toMERS-CoV infection, experimental data suggested theopposite [50].
Each natural and potential host for MERS-CoV infection is discussed below
in detail and summarized in Tables 1 and 2.
3.1. Camelids
Dromedary camels are themain source ofMERS-CoV zoonotic trans-
mission (reviewed in [52]). In experimental intranasal inoculationsFig. 1. Illustration of the known and potential host range of Middle East respiratory syndrome c
other species might act as hosts. In red: reportedMERS-CoV-seropositive species and/or specie
considered potential hosts since they are experimentally susceptible toMERS-CoV infection. Alp
of different sequences of MERS-CoV-like viruses have been found. Continuous arrows represe
represent potential inter-species transmission.with MERS-CoV, only mild clinical signs (i.e. nasal discharge) with
URT infection were observed. Viral RNA was detected in nasal swabs,
in upper and lower respiratory tracts, and also in extra-pulmonary tis-
sues (i.e. lymphnodes, tonsil, intestine, liver, adrenal gland, etc.). In con-
trast, infectious virus was only detected in the URT, trachea, large
bronchus and tracheobronchial lymph node. Gross lesions were not ob-
served in dromedary camels, but inﬂammation in the nasal cavity, tra-
chea and bronchus was present. The virus replication in dromedaries
was only detected in epithelial cells in the URT [47,53].
Llamas and alpacas, also known as domestic new world camelids,
developed a similar clinical-pathological picture to that of dromedaries
after experimental MERS-CoV infection. In both species the virus was
inoculated via intranasal route, and either no clinical signs (alpacas) or
mild mucus secretion (llamas) was observed. MERS-CoV was detected
in nasal swabs, and in the URT and trachea of both llamas and alpacas.
None of the species showed lesionsmacroscopically, butmicroscopical-
lymild to severe rhinitis was detected in alpacas aswell asmetaplasia of
the epithelium of the turbinate in alpacas. Similar to dromedaries, the
epithelial cells in theURTwere themain target cells for virus replication.
Concomitant to an antibody response, the virus was cleared from the
URT 7 to 10 days after experimental infection [48–50].
3.2. Non-camelid domestic species
After intranasal inoculation of MERS-CoV, only mild excretion of
mucus was observed in 6 to 8-week old domestic pigs [50]. Viral RNA
was detected in nasal swabs, in the URT, trachea and bronchus. Al-
though gross lesions were not present in pigs, they showed mild to
moderate rhinitis, with virus replication observed in the epithelial
cells in the URT. Shedding of MERS-CoV was detected in nasal swabs
from days 1 to 10 PI, but infectious virus was only detected until day 4
PI. Viral RNA was also detected in the URT, trachea and bronchus [50].oronavirus (MERS-CoV). Dromedary camel is a demonstrated reservoir of MERS-CoV, but
s in which virus has been naturally detected. In orange: other animal species that might be
acas ﬁt into both scenarios (red and orange). In black: animals (bats, to date) inwhich RNA
nt already described intra- and inter-species transmission events. Discontinuous arrows
Table 1
Summary of MERS-CoV shedding and presence of virus in different tissues in the potential animal reservoirs for MERS-CoV after experimental inoculation.
Species
Route and dose of
inoculation MERS-CoV shedding
MERS-CoV RNA in tissues
MERS-CoV antigen in tissues
Infectious
MERS-CoV in
tissues References
Camelids Dromedary camels
(Camelus
dromedarius)
IT, IN, conjunctival or IN
only; 107 TCID50
Viral RNA in NS (1
to 13 dpi)
Infectious virus in
NS (1 to 6 dpi)
URT, LRT, tracheal LN, pulmonary LN, cervical LN,
tonsil, PSG, intestine, liver, spleen, kidney, heart,
adrenal
Nasal respiratory epithelial cells
URT, trachea, large
bronchus, tracheal
LN
[47,53]
Alpacas (Vicugna
pacos)
IN; 107 PFU in 3 mL
saline solution
Infectious virus in
NS (1 to 5 dpi)
URT, trachea
Nasal respiratory epithelial cells
ND [48,49]
Llamas (Lama
glama)
IN; 107 TCID50 in 3 mL
saline solution
Viral RNA in NS (1
to 15 dpi)
Infectious virus in
NS (1 to 7 dpi)
URT, trachea and bronchus
Nasal respiratory epithelial cells
ND [50]
Non-camelid
domestic
species
Domestic pig (Sus
scrofa domesticus)
IN; 107 TCID50 in 3 mL
saline solution
Viral RNA in NS (1
to 10 dpi)
Infectious virus in
NS (1 to 4 dpi)
URT, trachea and bronchus
Nasal respiratory epithelial cells
ND [50]
Rabbit (Oryctolagus
cuniculus)
IN (1 × 106 TCID50), IT
(4 × 106 TCID50)
Viral RNA in NS (1
to 10 dpi)
Infectious virus in
NS (1 to 7 dpi)
Mainly in URT, LRT
Nasal respiratory and bronchiolar epithelial cells
ND [54]
NHP Rhesus macaques
(Macaca mulatta)
IT, OC, oral, IN; 7 × 106
TCID50/IT, 6,5 × 107
TCID50
Viral RNA in NS, BAL
samples, and few OS
URT, lung, mediastinal LN
Type I and II pneumocytes, alveolar MΦ
Lung [21–23]
Common marmoset
(Callithrix jacchus)
OC, oral, IT, IN; 5 ×
106/IT, 5 × 107 TCID50
Viral RNA in NS and
OS
URT, lung, mediastinal LN, blood
Type I pneumocytes, alveolar MΦ
Nasal mucosa,
trachea, lung
[24,55]
Abbreviations: BAL, bronchoalveolar lavages; dpi, days post inoculation; IN, intranasal; IT, intratracheal; LN, lymph node; LRT, lower respiratory tract; MΦ, macrophages; ND, non-deter-
mined; NHP, non-humanprimates; NS, nasal swabs; OC, ocular; OS, oropharyngeal swabs; PFU, plaque-forming units; PSG, parotid salivary gland; RNA, ribonucleic acid; TCID50, 50% tissue
culture infectious dose; URT, upper respiratory tract.
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gross lesions at necropsy after experimental MERS-CoV inoculation;
thus, they were considered an animal model of asymptomatic infection
[54]. Similar to pigs, mild to moderate rhinitis with necrosis was ob-
served, and respiratory epithelial cells in the URT were identiﬁed as
the target cells for MERS-CoV replication. Viral RNA was present in
nasal swabs, and upper and lower respiratory tracts. Infectious virus
was also detected in nasal swabs up to 7 days PI [54].
3.3. Non-human primates
The rhesus macaque was used as the ﬁrst animal model developed
for MERS-CoV infection, showing mild to moderate respiratory disease
from day 1 to 4 PI after intratracheal inoculation [21]. Gross lesionsTable 2
Summary of clinical signs, pathological ﬁndings and target cells in tissues of natural and poten
Species Clinical signs Gross ﬁndings Histopath
Camelids Dromedary camels
(Camelus
dromedarius)
Mild respiratory
disease, nasal
discharge
Not present Multifoca
with epit
and tons
Alpacas (Vicugna
pacos)
Not observable Not present Squamou
turbinate
Llamas (Lama
glama)
Mild mucus
secretion in one
nostril
Not present Mild to s
Non-camelid
domestic
species
Domestic pig (Sus
scrofa domesticus)
Mild excretion of
mucus in the nose
Not present Mild to s
Rabbit (Oryctolagus
cuniculus)
Not observable Not present Focal mil
NHP Rhesus macaquesa
(Macaca mulatta)
Fever, mild to
moderate
respiratory disease
Lung congestion
and nodules in
lung
No extra
pulmonary
lesions
Multifoca
Common
marmoseta
(Callithrix jacchus)
Mild to severe
respiratory disease
Congestion of
bronchioles
Diffuse in
bronchoi
Abbreviations: NHP, non-human primates; URT, upper respiratory tract.
a Also animal models of disease (translation to human).were present only in the lung, consisting in congestion and presence
of nodules, and the main observed microscopical lesion was interstitial
pneumonia. Although MERS-CoV RNA was detected in nasal swabs,
bronchoalveolar lavage samples, oropharyngeal swabs, and also in
some upper and lower respiratory tract tissue samples, infectious
virus was only isolated from the lungs. MERS-CoV replication occurred
in type I and II pneumocytes, and viral antigen co-localized with sites
of pneumonia [21]. Macaques represent a useful model to study mild
MERS-CoV infection because they develop a transient respiratory dis-
ease similar to humans.
On the other hand, common marmosets exhibited moderate to se-
vere respiratory disease from 1 to 13 days after inoculation of MERS-
CoV through multiple routes (ocular, oral, intratracheal and intranasal)
[24]. Similar to macaques, gross ﬁndings were present only in the lungtial reservoir hosts for MERS-CoV infection as experimental animal models.
ological lesions Target cells in tissues References
l moderate rhinitis, tracheitis and bronchitis
helial necrosis. Hyperplasia of lymph nodes
il
Respiratory epithelial
cells in the URT
[47,53]
s metaplasia of the epithelium of the
. Hypertrophy and hyperplasia of lymph nodes
Respiratory epithelial
cells in the URT
[48,49]
evere rhinitis Respiratory epithelial
cells in the URT
[50]
evere rhinitis Respiratory epithelial
cells in the URT
[50]
d to moderate rhinitis with necrosis Respiratory epithelial
cells in the URT
[54]
l mild-to-moderate interstitial pneumonia Type I and II
pneumocytes and
alveolar macrophages
[21,22,23]
terstitial inﬁltration in lower lung lobes,
nterstitial pneumonia
Type I pneumocytes
and alveolar
macrophages
[24]
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MERS-CoV antigen was detected by immunohistochemistry in both
type I and II pneumocytes and alveolar macrophages, but the virus rep-
licated only in type I pneumocytes and macrophages. Similar results
were observed in marmosets after inoculation of MERS-CoV only via
intratracheal route [55]. However, the outcome of MERS-CoV infection
in marmosets has been controversial after the publication of a recent
study by Johnson and collaborators, which demonstrated no lethality
after intratracheal inoculation [56]. The outcome of experimental infec-
tions in both species is reviewed in recent publications [17–20].
4. Advantages and disadvantages of animal hosts used forMERS-CoV
experimental infection
As described in the previous section, a number of animal species
have been described as either natural reservoir (dromedary camel) or
potential intermediate hosts of MERS-CoV, each one with its beneﬁts
and limitations (Table 3) when used as experimental infection models.
Camelids (dromedary camels, alpacas and llamas), non-camelid domes-
tic species (pigs and rabbits), and NHP (rhesus macaques and common
marmosets) have been experimentally demonstrated to be susceptible
to MERS-CoV infection, but with differences among them [21–24,47–
50,53,54]. Experiments with dromedary camels, the natural MERS-CoV
host, and probably theﬁrst target for controllingMERS through vaccina-
tion [53], are costly and represent a high security risk for animal care-
takers because of the difﬁculty in handling these animals under
appropriate biosafety conditions. The main advantages of using the
llama or alpaca models are that both belong to the family Camelidae,
have smaller size, more gentle behavior, and are more available at a
commercial level than dromedary camels; importantly, speciﬁc re-
agents for immune monitoring have been developed for new world
camelids [57]. Therefore, theymay be useful surrogates for dromedaries
under experimental conditions. However, both models are also quiteTable 3
Advantages and limitations of natural and potential intermediate hosts for MERS-CoV infection
Species Advantages
Camelids Dromedary camels (Camelus
dromedarius)
• Natural host for MERS-CoV
• Efﬁcient animal-to-animal transm
Alpacas (Vicugna pacos) • Potential surrogates for dromeda
(potential hosts for MERS-CoV)
• Efﬁcient animal-to-animal transm
Llamas (Lama glama) • Potential surrogates for dromeda
(potential hosts for MERS-CoV)
Non-camelid
domestic species
Domestic pig (Sus scrofa
domesticus)
• Relative low cost and readily avai
• Ease handling
• Potential surrogates for dromeda
(potential hosts for MERS-CoV)
• Animal-to-animal transmission (e
• Pig-speciﬁc immunological reage
Rabbit (Oryctolagus
cuniculus)
• Low cost and readily available
• Ease handling
• Potential surrogates for dromeda
(potential hosts for MERS-CoV)
• Rabbit-speciﬁc immunological rea
NHP Rhesus macaques (Macaca
mulatta)
• Human-speciﬁc immunological re
• Clinical disease similar to humans
species transmission)
Common marmoset
(Callithrix jacchus)
• Some human-speciﬁc immunolog
• Clinical disease similar to humans
species transmission)
Abbreviations: BSL3, biosafety level 3; MERS-CoV, Middle East respiratory syndrome; NHP, nonexpensive and require large and complex BSL3 facilities. In contrast to
camelids, other domestic species such as pigs and rabbits are readily
available, with lower cost and easier handling. Additionally, an exten-
sive panel of speciﬁc-immunological reagents is available for these spe-
cies. When compared to camelids, however, lower MERS-CoV titers
were detected in nasal cavities and tissue samples of pigs and rabbits
during the infection. Furthermore their usefulness as animal models
for transmission studies has not yet been addressed.
Contrary to the mentioned species, both macaques and common
marmosets develop clinical disease relatively similar to humans. In
that respect, phylogenetically-related species as baboons [58], which
live in Africa and Arabic Peninsula, might also play a role in the trans-
mission of the virus. However, little attention has been paid to these
species since no sero-epidemiology has been documented. There are
important limitations when working with NHP models, namely the
complex husbandry requirements that lead to substantially increased
costs, some controversy results among different groups. Besides practi-
cal considerations, human-speciﬁc immunological reagents cross-react
with NHP species and are widely available.5. Conclusion and future steps
As summarized in this review, several species of animals are suscep-
tible to experimental MERS-CoV infection; thus, they might act as po-
tential intermediate hosts of the disease. However, the presence of
viral RNA and/or speciﬁc antibodies against the virus has been only
demonstrated in the ﬁeld in dromedaries and alpacas [41,51]. At the
light of recent experimental studies, it seems that the list of potential
host targets for MERS-CoV is not closed. MERS surveillance programs
should be implemented in endemic areas in animal species for which
experimental evidence of susceptibility has been provided and species
closely related to them.as experimental animal models as well as for transmission studies.
Limitations
ission (ﬁeld studies)
• Expensive and limited availability
• Complex husbandry requirements (large
BSL3 facilities)
ries under experimental conditions
ission (experimental)
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• No animal-to-animal transmission studies
available
lable
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nts are available
• Complex husbandry requirements (large
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• Limited transmission (only via direct contact,
and during few days)
• Lower viral titers in NS and tissues upon
infection
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• No animal-to-animal transmission studies
available
• Lower viral titers in NS and tissues upon
infection
agents are widely available
: translational research (for intra
• Expensive and limited availability
• Complex husbandry requirements (large
BSL3 facilities)
• No animal-to-animal transmission studies
available
ical reagents cross-react
: translational research (for intra
• Expensive and limited availability
• Complex husbandry requirements (large
BSL3 facilities);
• No animal-to-animal transmission studies
available
-human primates; NS, nasal swabs.
39J. Vergara-Alert et al. / One Health 3 (2017) 34–40SARS and MERS outbreaks taught us many lessons, and one of the
most important is that, even in the absence of an overt threat, there is
the possibility of the re-emergence of a virus or other similar viruses.
On the other hand, and since the ﬁrst case of MERS, continuous new
cases have been described in different countries around the world
[59–62]. This underlines the importance of the development of animal
models closer to the natural host targets. The key role of domestic ani-
mals and wildlife in the transmission of MERS-CoV should be further
elucidated; meanwhile, countermeasures against deadly coronaviruses
must be further explored since the risk of a global outbreak is not neg-
ligible. Noteworthy, after more than a decade of SARS and ﬁve years of
MERS epidemics, there are still no licensed preventive or therapeutic
drugs available that could be used in case of an eventual re-emergence
of SARS or MERS. This scenario is not the outcome of technical issues,
since effective vaccine prototypes against those pathogens are already
available [53,63,64]. In case of MERS-CoV, vaccination of dromedary
camels, the main source of zoonotic transmission, might be useful to
control the spread of MERS [53]. However, when developing a vaccine,
besides testing the protection efﬁcacy, researchers need to think about
social problems such as the reticence of camel owners to vaccinate
their animals. Thus, the development of a dual vaccine able to protect
against both, MERS-CoV and camelpox virus (an endemic disease in
theMiddle East, Africa and Asia)might be an ideal solution [53]. Recent-
ly, another dual-vaccine for humans and animals againstMERS-CoV and
rabies virus has been designed [65]. Political aspects have also a key role
in the release of a vaccine into themarket. Unless the requirements and
timings for vaccine licensing procedures are facilitated, pharmaceutical
companieswill unlikely invest in their development taking into account
the current market demand. Moreover, fragmentation of intellectual
property rights may also adversely affect the development of vaccines
to combat those infections [66].
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